Literature DB >> 2838016

Monoclonal-antibody-mediated enzyme-linked immunosorbent assay for detection of reticuloendotheliosis viruses.

Z Z Cui1, L F Lee, E J Smith, R L Witter, T S Chang.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) is described for the detection of reticuloendotheliosis viruses (REVs). The assay uses a mixture of monoclonal antibodies (MCAs) prepared against a 62-kilodalton REV envelope glycoprotein (gp62) to capture antigen, rabbit anti-REV serum as detection antibody, and peroxidase-conjugated anti-rabbit IgG as indicator antibody. The MCAs were reactive with REV strain T, chick syncytial virus, and duck infectious anemia virus but unreactive against Marek's disease and avian leukosis viruses. The ELISA was compared with complement fixation test and REV immunofluorescent assay of infected fibroblasts, plasmas, and egg albumen from infected chickens. The lower limit of gp62 detection was about 120 ng of REV protein. Limit dilution of infectious REV was detected after 7-8 days of cultivation of infected fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838016

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  3 in total

1.  Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency.

Authors:  Xiaoping Cui; Lucy F Lee; Willie M Reed; Hsing-Jien Kung; Sanjay M Reddy
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Retroviral insertional activation in a herpesvirus: transcriptional activation of US genes by an integrated long terminal repeat in a Marek's disease virus clone.

Authors:  D Jones; P Brunovskis; R Witter; H J Kung
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

3.  Protection induced by a gp90 protein-based vaccine derived from a Reticuloendotheliosis virus strain isolated from a contaminated IBD vaccine.

Authors:  Zhihao Ren; Fanfeng Meng; Qiuchen Li; Yixin Wang; Xiaofeng Liu; Zhizhong Cui; Shuang Chang; Peng Zhao
Journal:  Virol J       Date:  2018-03-12       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.